The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Developing new drugs for IBS is also difficult because of the lack of biomarkers and endpoints, which implies high placebo response rates, which do not facilitate pharmaceutical companies’ investment in this field [57,58,59].”
From Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies (2025) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Self-citationGlobal Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Slattery, S. A., Niaz, O., Aziz, Q., Ford, A. C., & Farmer, A. D. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13227 · Cited by 214
Chey, W. D., Nojkov, B., Rubenstein, J. H., Dobhan, R. R., Greenson, J. K., & Cash, B. D. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.55 · Cited by 175
Self-citationPimentel, M., Morales, W., Rezaie, A., Marsh, E., Lembo, A., Mirocha, J., Leffler, D. A., Marsh, Z., Weitsman, S., Chua, K. S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126438 · Cited by 148
Research works printed but not linked: 80
- Spiegel, 2010, Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts, Am J Gastroenterol, 105, 848, 10.1038/ajg.2010.47 · DOI
- Ford, 2014, American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am J Gastroenterol, 109, S2, 10.1038/ajg.2014.187 · DOI
- Weinberg, 2014, American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome, Gastroenterology, 147, 1146, 10.1053/j.gastro.2014.09.001 · DOI
- Spiegel, 2009, The burden of IBS: looking at metrics, Curr Gastroenterol Rep, 11, 265, 10.1007/s11894-009-0039-x · DOI
- Koloski, 2001, Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors, Am J Gastroenterol, 96, 1340, 10.1111/j.1572-0241.2001.03789.x · DOI · Paper page
- Everhart, 2009, Burden of digestive diseases in the United States part II: lower gastrointestinal diseases, Gastroenterology, 136, 741, 10.1053/j.gastro.2009.01.015 · DOI
- Agarwal, 2011, The effect of irritable bowel syndrome on health-related quality of life and health care expenditures, Gastroenterol Clin North Am, 40, 11, 10.1016/j.gtc.2010.12.013 · DOI
- Sood, 2015, Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers, Aliment Pharmacol Ther, 42, 491, 10.1111/apt.13283 · DOI
- Mearin, 2016, Bowel disorders, Gastroenterology
- Ford, 2008, Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis, Gut, 57, 1545, 10.1136/gut.2008.159723 · DOI · Paper page
- Ford, 2015, Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care, Am J Gastroenterol, 110, 716, 10.1038/ajg.2015.117 · DOI
- Simpkins, 2017, Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care, Aliment Pharmacol Ther, 45, 91, 10.1111/apt.13846 · DOI
- Loftus, 2016, Update on the incidence and prevalence of inflammatory bowel disease in the United States, Gastroenterol Hepatol (N Y), 12, 704
- Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI
- 2004, NIH Consensus Development Conference on Celiac Disease, NIH Consens State Sci Statements, 21, 1
- Fasano, 2003, Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study, Arch Intern Med, 163, 286, 10.1001/archinte.163.3.286 · DOI
- Bates, 2015, Fitting linear mixed-effects models using lme4, J Stat Softw, 67, 1
- Catassi, 2007, Detection of celiac disease in primary care: A multicenter case-finding study in North America, Am J Gastroenterol, 102, 1454, 10.1111/j.1572-0241.2007.01173.x · DOI
- Dickey, 1998, Identification of coeliac disease in primary care, Scand J Gastroenterol, 33, 491, 10.1080/00365529850172043 · DOI
- Kalantari, 2015, Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome, Advanced Biomedical Research, 4, 85, 10.4103/2277-9175.156647 · DOI
- Langenberg, 2014, Distinguishing tropical sprue from celiac disease in returning travellers with chronic diarrhoea: a diagnostic challenge?, Travel Med Infect Dis, 12, 401, 10.1016/j.tmaid.2014.05.001 · DOI
- Otten, 2008, Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. [Erratum appears in Clin Chem Lab Med. 2008;46(12):1798], Clin Chem Lab Med, 46, 1275
- Yagil, 2005, Serologic testing for celiac disease in young adults—a cost-effect analysis, Dig Dis Sci, 50, 796, 10.1007/s10620-005-2576-y · DOI
- Caccaro, 2014, Fecal lactoferrin and intestinal permeability are effective non-invasive markers in the diagnostic work-up of chronic diarrhea, BioMetals, 27, 1069, 10.1007/s10534-014-9745-4 · DOI
- Carroccio, 2003, Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children, Clin Chem, 49, 861, 10.1373/49.6.861 · DOI
- Carroccio, 2002, Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study, Clinical Chemistry, 48, 1546, 10.1093/clinchem/48.9.1546 · DOI
- Cash, 2011, The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls, Gastroenterology, 141, 1187, 10.1053/j.gastro.2011.06.084 · DOI
- Caviglia, 2014, Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders, Scand J Gastroenterol, 49, 1419, 10.3109/00365521.2014.934913 · DOI
- Costa, 2003, Role of faecal calprotectin as non-invasive marker of intestinal inflammation, Digest Liver Dis, 35, 642, 10.1016/S1590-8658(03)00381-5 · DOI · Paper page
- Dickey, 1997, Association between serum levels of total IgA and IgA class endomysial and antigliadin antibodies: implications for coeliac disease screening, Eur J Gastroenterol Hepatol, 9, 559, 10.1097/00042737-199706000-00002 · DOI
- Dolwani, 2004, Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology, Aliment Pharmacol Ther, 20, 615, 10.1111/j.1365-2036.2004.02128.x · DOI
- Hadithi, 2007, Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease, Ann Intern Med, 147, 294, 10.7326/0003-4819-147-5-200709040-00003 · DOI
- Hopper, 2007, Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool, Bmj, 334, 729, 10.1136/bmj.39133.668681.BE · DOI
- Kaiser, 2007, Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome, Gut, 56, 1706, 10.1136/gut.2006.113431 · DOI
- Kane, 2003, Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation, Am J Gastroenterol, 98, 1309, 10.1111/j.1572-0241.2003.07458.x · DOI · Paper page
- Langhorst, 2008, Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices, Am J Gastroenterol, 103, 162, 10.1111/j.1572-0241.2007.01556.x · DOI · Paper page
- Poullis, 2002, A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders, Eur J Gastroenterol Hepatol, 14, 409, 10.1097/00042737-200204000-00013 · DOI
- Rashtak, 2008, Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods, Aliment Pharmacol Ther, 28, 805, 10.1111/j.1365-2036.2008.03797.x · DOI
- Schoepfer, 2008, Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies, Inflamm Bowel Dis, 14, 32, 10.1002/ibd.20275 · DOI · Paper page
- Schroder, 2007, Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin, Aliment Pharmacol Ther, 26, 1035, 10.1111/j.1365-2036.2007.03457.x · DOI
- Shahbazkhani, 2003, Coeliac disease presenting with symptoms of irritable bowel syndrome, Aliment Pharmacol Ther, 18, 231, 10.1046/j.1365-2036.2003.01666.x · DOI
- Shine, 1985, C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders, Clin Chim Acta, 148, 105, 10.1016/0009-8981(85)90219-0 · DOI
- Sidhu, 2010, Faecal lactoferrin—a novel test to differentiate between the irritable and inflamed bowel?, Aliment Pharmacol Ther, 31, 1365, 10.1111/j.1365-2036.2010.04306.x · DOI
- Tesei, 2003, Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies, Aliment Pharmacol Ther, 17, 1415, 10.1046/j.1365-2036.2003.01595.x · DOI
- Tibble, 2000, A simple method for assessing intestinal inflammation in Crohn's disease, Gut, 47, 506, 10.1136/gut.47.4.506 · DOI
- Valdimarsson, 1996, Is small bowel biopsy necessary in adults with suspected celiac disease and IgA anti-endomysium antibodies? 100% positive predictive value for celiac disease in adults, Dig Dis Sci, 41, 83, 10.1007/BF02208588 · DOI
- Wahnschaffe, 2007, Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, 844, 10.1016/j.cgh.2007.03.021 · DOI
- Wassell, 2004, Faecal calprotectin: a new marker for Crohn's disease?, Ann Clin Biochem, 41, 230, 10.1258/000456304323019613 · DOI
- Chang, 2014, Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome, Mol Med Rep, 10, 522, 10.3892/mmr.2014.2180 · DOI
- Merrick, 1985, Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention, Br Med J (Clin Res Ed), 290, 665, 10.1136/bmj.290.6469.665 · DOI
- Oikonomou, 2012, Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity, J Gastroenterol, 47, 519, 10.1007/s00535-011-0516-5 · DOI
- Sciarretta, 1986, Use of 23-selena-25-homocholyltaurine to detect bile acid malabsorption in patients with illeal dysfunction or diarrhea, Gastroenterology, 91, 1, 10.1016/0016-5085(86)90431-2 · DOI
- Sciarretta, 1987, 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit, Gut, 28, 970, 10.1136/gut.28.8.970 · DOI
- Schmulson, 2016, Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico, Rev Gastroenterol Mexico, 81, 236
- Valentin, 2016, Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis, Gut, 65, 1951, 10.1136/gutjnl-2015-309889 · DOI
- Soares, 2016, Giardiasis: an update review on sensitivity and specificity of methods for laboratorial diagnosis, J Microbiol Methods, 129, 98, 10.1016/j.mimet.2016.08.017 · DOI
- McHardy, 2014, Detection of intestinal protozoa in the clinical laboratory, J Clin Microbiol, 52, 712, 10.1128/JCM.02877-13 · DOI
- Kappelman, 2007, The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States, Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 · DOI · Paper page
- Menees, 2015, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS, Am J Gastroenterol, 110, 444, 10.1038/ajg.2015.6 · DOI · Paper page
- Bibbins-Domingo, 2017, Screening for celiac disease: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 1252, 10.1001/jama.2017.1462 · DOI
- Dube, 2005, The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review, Gastroenterology, 128, S57, 10.1053/j.gastro.2005.02.014 · DOI
- Rubio-Tapia, 2009, Increased prevalence and mortality in undiagnosed celiac disease, Gastroenterology, 137, 88, 10.1053/j.gastro.2009.03.059 · DOI · Paper page
- West, 2004, Malignancy and mortality in people with coeliac disease: population based cohort study, Bmj, 329, 716, 10.1136/bmj.38169.486701.7C · DOI · Paper page
- Rubio-Tapia, 2013, ACG clinical guidelines: diagnosis and management of celiac disease, Am J Gastroenterol, 108, 656, 10.1038/ajg.2013.79 · DOI
- Bai, 2013, World Gastroenterology Organisation global guidelines on celiac disease, J Clin Gastroenterol, 47, 121, 10.1097/MCG.0b013e31827a6f83 · DOI
- Hill, 2016, NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-Related Disorders, J Pediatr Gastroenterol Nutr, 63, 156, 10.1097/MPG.0000000000001216 · DOI
- McGowan, 2008, Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic, Clin Chem, 54, 1203, 10.1373/clinchem.2008.103606 · DOI
- Vijayvargiya, 2013, Methods for diagnosis of bile acid malabsorption in clinical practice, Clin Gastroenterol Hepatol, 11, 1232, 10.1016/j.cgh.2013.04.029 · DOI
- Mottacki, 2016, Review article: bile acid diarrhoea—pathogenesis, diagnosis and management, Aliment Pharmacol Ther, 43, 884, 10.1111/apt.13570 · DOI
- Pattni, 2012, Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea, Clin Transl Gastroenterol, 3, e18, 10.1038/ctg.2012.10 · DOI
- Mosli, 2012, Nonutility of routine testing of stool for ova and parasites in a tertiary care Canadian centre, Can J Microbiol, 58, 653, 10.1139/w2012-039 · DOI
- Perry, 2017, Evaluation of the BD MAX Enteric Parasite Panel for the detection of Cryptosporidium parvum/hominis, Giardia duodenalis and Entamoeba histolytica, J Med Microbiol, 66, 1118, 10.1099/jmm.0.000558 · DOI
- Pimentel, 2008, A new rat model links two contemporary theories in irritable bowel syndrome, Dig Dis Sci, 53, 982, 10.1007/s10620-007-9977-z · DOI
- Pardi, 2017, Diagnosis and management of microscopic colitis, Am J Gastroenterol, 112, 78, 10.1038/ajg.2016.477 · DOI
- Genta, 2015, The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea, Eur J Gastroenterol Hepatol, 27, 963, 10.1097/MEG.0000000000000365 · DOI
- Kamp, 2016, Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 14, 659, 10.1016/j.cgh.2015.09.031 · DOI
- Hilmi, 2013, Low prevalence of ‘classical' microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea, BMC Gastroenterol, 13, 80, 10.1186/1471-230X-13-80 · DOI
- Ozdil, 2011, The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome, BMC Gastroenterol, 11, 96, 10.1186/1471-230X-11-96 · DOI
- Tuncer, 2003, Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome, Acta Gastroenterol Belg, 66, 133
- Cantarini, 2012, Ileocolorectal inflammation and psychopathological status in patients with diarrhea-predominant functional bowel disorders, Neurogastroenterol Motil, 24, 103
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationLembo, A., Sultan, S., Chang, L., Heidelbaugh, J. J., Smalley, W., & Verne, G. N. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.017 · Cited by 192
Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies
Abalo, R., Gallego-Barceló, P., & Gabbia, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199345 · Cited by 5
Metadata
- Authors
- Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y., Surawicz, C. M., & Chey, W. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 157
- Issue
- 3
- Pages
- 859-880
- ISSN
- 0016-5085
- Cited by
- 76
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Working Dog Centre, Massey University
- Administration for Community Living (CMS)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). https://app.cochat.ai/papers/10.1053/j.gastro.2019.06.014
- The paper
- Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y., Surawicz, C. M., & Chey, W. D. (2019). AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology. https://doi.org/10.1053/j.gastro.2019.06.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.